Project Grant HT94252510849
Award Date
9/1/25
Completion Date
8/31/27
Dollars Obligated
$384K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Phoenix, AZ 85004, USA
Similar Awards
The U.S. Defense Health Agency awarded a $192,000 Project Grant (CFDA 12.420 - Military Medical Research and Development) to the Translational Genomics Research Institute (TGen) on September 1, 2025. The grant supports TGen's research project titled "SINGLE: Signature Enabling Glioma Enrollment", which aims to conduct advanced biomedical research to transform healthcare for military service members, veterans, and the broader public. The project will focus on investigating medical...
The Defense Health Agency awarded a $1,535,920.00 Project Grant to the Translational Genomics Research Institute (TGen) under the Military Medical Research and Development program (CFDA 12.420). The grant supports TGen's research on genomic structural mutations associated with telomere dysfunction in glioblastoma cells and patients. The 4-year project will utilize advanced genomic analysis and sequencing techniques to gain insights into the molecular mechanisms driving glioblastoma, a highly...
The U.S. Defense Health Agency awarded a $909,510 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to The Geneva Foundation, a non-profit research organization in Tacoma, Washington. The grant supports advanced biomedical research to develop precision therapy for the eradication of brain metastatic breast cancer. The 3-year grant, running from May 2025 to April 2028, will fund innovative research, development, and clinical support services focused on...
The Defense Health Agency awarded a $1,009,750.00 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Geneva Foundation in Tacoma, Washington. The grant, awarded on August 1, 2025, supports the "Genomic and Functional Characterization of Chemoresistance in Small Cell Lung Cancer" research project with a completion date of July 31, 2028. The Geneva Foundation, a non-profit organization focused on medical research and development for the U.S....
The Defense Health Agency awarded a $352,000 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to the Sloan-Kettering Institute for Cancer Research. The grant, titled "AUGMENTING IN VIVO EFFICACY OF A NOVEL LANOSTEROL SYNTHASE INHIBITOR IN GLIOBLASTOMA", will support advanced biomedical research to investigate innovative treatments for glioblastoma, a type of brain cancer. The research, spanning from September 2025 to August 2027, aims to...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,002,591.00 to Targepeutics, Inc. to determine the intratumoral drug distribution of the immunotoxin GB13 for the treatment of adult and pediatric brain cancers. The 3-year project aims to transform health care for Service Members and the American public through innovative and impactful biomedical research on medical solutions for the battlefield. The...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $771,627 project grant to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct advanced biomedical research on tuning and strike targeting of glioblastoma. The 24-month award period runs from August 1, 2025 to July 31, 2027. As a leading academic medical center and recipient of significant federal research funding, Massachusetts General Hospital will...
The Defense Health Agency awarded a $1,116,955 Project Grant to The Broad Institute, Inc. to identify new therapies and therapeutic targets in gastroesophageal cancer. This 3-year grant, running from August 15, 2023 to August 14, 2026, is funded through the Military Medical Research and Development program (CFDA 12.420). The Broad Institute, a non-profit biomedical and genomic research organization, will leverage its expertise in areas like genomic sequencing, data analysis, and translational...
The Washington University Office of Sponsored Research Services Division was awarded a $1,377,119 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct the study "AD GENETIC RISK AS A PROGNOSTIC FACTOR FOR COGNITIVE OUTCOMES AFTER TBI" over a 4-year period from September 2024 to September 2028. This federal grant supports innovative biomedical research aimed at improving health outcomes for military service...
This $240,897 Project Grant, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, will support integrative transcriptomic and epigenomic profiling of subependymal giant cell astrocytoma at single-cell resolution. The award was made to Duke University's Office of Research Administration on August 1, 2025, with a period of performance through July 31, 2027. The Military Medical Research and Development program funds advanced biomedical...